DDX53 and neoplasm: In an in vivo model, mice with CT26 tumors were treated with three doses of ASIV (15.0 mg/kg) every three days, resulting in reduced tumor growth, as evidenced by decreased tumor volume and weight compared to PBS-treated controls.